Microbiome in Inflammatory Bowel Disease (IBD)

Dear Colleagues,

It is well known that the incidence of inflammatory bowel disease (IBD) is increasing significantly in developing countries, while in others, it has now reached a plateau. This increase is largely related to environmental factors which in turn affect the human intestinal microbiome. The resulting dysbiosis increases the growth of opportunistic pathogens in the intestinal lumen, resulting in abnormal immune responses, thus promoting the onset of IBD. The purpose of this Special Issue is to define the role of the gut microbiome in the pathogenesis of IBD so that a more personalized therapeutic approach through exogenous modification of the gut microbiome could be possible shortly. An attempt will also be made to indicate the microorganisms that may participate in the disease pathogenesis, as well as the current therapeutic position of fecal transplantation, the relationship of nutritional interventions in IBD, and their effect on the composition of the intestinal microbiome.

We cordially invite authors to submit original research and review articles focusing on this important and rapidly expanding field of biomedicine. Potential topics include but are not limited to:

• Gut microbiome, dysbiosis, and pathogenesis of IBD;
• Probiotics and gut microbiome;
• Fecal transplantation in the treatment of IBD;
• Potential link between gut microbiome, COVID-19, and outcome of IBD;
• Extraintestinal manifestations of IBD: Is there any link with the gut microbiome?
• Intestinal yersiniosis, probiotics, and gut microbiome;
• Autophagy, gut microbiome, and IBD;
• Inflammasomes, IBD, and gut microbiome;
• Nutritional aspects and gut microbiome in IBD: the role of the Mediterranean diet;
• Vitamin D and intestinal homeostasis: the role of gut microbiome.

Prof. Dr. John K. Triantafillidis
Dr. Ferenc Sipos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• inflammatory bowel disease
• ulcerative colitis
• Crohn’s disease
• gut microbiome
• pathogenesis of IBD
• nutrition
• probiotics
• COVID-19
• fecal transplantation
• intestinal yersiniosis